# VIRO-25 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/viro-25

> VIRO-25, sponsored by GENELUX Corp (GNLX): 3 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | VIRO-25 |
| Codes | VIRO-25 |
| Sponsor | GENELUX Corp (GNLX) https://sec-api.dev/companies/gnlx/catalysts |
| Indications | recurrent nsclc |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Oct 2024: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: recurrent NSCLC.
- First seen 2025-05-06, last confirmed 2025-05-06.
- SEC Form 10-Q (accession 0001641172-25-008838): "Newsoara is generally obligated under our license agreement with Newsoara, dated September 27, 2021 (the "Newsoara License Agreement") to fund a Phase 2, open-label, randomized, and controlled clinical trial designed to evaluate the efficacy and safety of intravenously delivered Olvi-Vec oncolytic VACV for patients with recurrent NSCLC in the United States, which VIRO-25 trial is now ongoing with the first patient dosed in October 2024." https://www.sec.gov/Archives/edgar/data/1231457/000164117225008838/form10-q.htm

### 2H 2025: interim data readout

- Status: scheduled. Date confidence: half.
- First seen 2025-03-28, last confirmed 2025-03-28.
- SEC Form 10-K (accession 0001641172-25-001184): "We expect to report interim results from the NSCLC trial in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1231457/000164117225001184/form10-k.htm

### 2H 2025: topline data readout

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2024-11-14, last confirmed 2025-03-25.
- SEC Form 8-K (accession 0001641172-25-000528): "For the Company's Phase 2 VIRO-25 trial in the United States, the Company anticipates reporting a readout of interim results in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1231457/000164117225000528/form8-k.htm
- SEC Form 10-Q (accession 0001493152-24-045790): "3 trial with topline results anticipated in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1231457/000149315224045790/form10-q.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/viro-25.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "VIRO-25 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/viro-25

```bibtex
@misc{secapidev_pdufa_viro_25_20261116,
  title        = {VIRO-25 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/viro-25}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_viro_25_20261116","title":"VIRO-25 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/viro-25","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
